Abstract: The present invention relates to antibodies that specifically bind to one or more of IL-4, IL-13, IL-33, TSLP, and p40. The present invention further relates to antibodies that bind to one of IL-4, IL-13, IL-33, or TSLP. The invention further relates to multispecific antibodies that specifically bind to IL-4 and IL-13, and at least one other target. The present invention relates to multispecific antibodies that bind IL-4, IL-13, and one of IL-33, TSLP, or p40. The present invention also pertains to related molecules, e.g. nucleic acids which encode such antibodies or multispecific antibodies, compositions, and related methods, e.g., methods for producing and purifying such antibodies and multispecific antibodies, and their use in diagnostics and therapeutics.

Abstract: A method for recognizing a reference point associated with a fiducial marker including the steps of: obtaining or receiving image data of the fiducial marker; determining the degree of which the image data of the fiducial marker is aligned with one or more reference images; of which if the degree of alignment is determined to be less than an acceptable threshold predicting a set of coordinates of the reference point associated with the fiducial marker; incorporating the set of coordinates with the image data to form a modified image data; and determining the degree of which the modified image data of the fiducial marker is aligned with one or more reference images.

Abstract: The present invention relates to stable formulations comprising antibodies or antigen-binding fragments thereof that bind to respiratory syncytial virus (RSV). Also provided are methods of preventing and/or treating RSV-related diseases with the formulations of the invention.

Abstract: Provided is a method of determining the stability increase provided by a non-reducing sugar in a pharmaceutical composition containing a protein therapeutic, the method comprising: (i) providing: a first pharmaceutical composition comprising an aqueous solution of the protein therapeutic in the substantial absence of a non-reducing sugar, wherein the first pharmaceutical composition has a first B22 value and a second pharmaceutical composition comprising an aqueous solution of the protein therapeutic and the non-reducing sugar, wherein the second pharmaceutical composition has a second B22 value; (ii) determining the difference between the first and second B22 values; and (iii) predicting the stability increase provided by the non-reducing sugar based on the difference in B22 values.

Abstract: The present invention relates to stable formulations of antibodies against T cell immunoreceptor with Ig and ITIM domains (TIGIT), optionally further containing an anti-human programmed death receptor 1 (PD-1) antibody or antigen binding fragment thereof. Also provided are methods of treating various cancers and chronic infections with the formulations of the invention.

Abstract: The invention relates to stable formulations comprising antibodies or antigen binding fragments thereof that bind to cytotoxic T lymphocyte associated antigen 4 (CTLA4), optionally further containing an anti-human programmed death receptor 1 (PD-1) antibody or antigen binding fragment thereof. Also provided are methods of treating various cancers and chronic infections with the formulations of the invention.

Abstract: Described are methods, systems and computer-readable media storing instructions that when executed on one or more processors execute a process for generating second program code in a statically typed programming language from first program code in a dynamically typed programming language. The first program code contains or, when executed, generates or operates on a dynamically typed array. The second program code may be generated by classifying the dynamically typed array into one of multiple categories, such as homogeneous, heterogeneous, or another, based on the array contents, array usage, and/or user input, and generating the second program code in the statically typed programming language based on the classification(s).

Abstract: System and method for estimating package implementation effort of software development life cycle (SDLC) activities are disclosed. In an embodiment, information associated with a plurality of configuration parameters of a SDLC activity is obtained. The configuration parameters include an organization, an industry vertical, business criticality of functionalities within the industry vertical, influencing factors and a utilization factor. Further, one or more of configuration factors associated with the SDLC activity are determined based on the information associated with the configuration parameters. Furthermore, functional effort for configuration of the SDLC activity is estimated based on the configuration factors. In addition, information associated with a plurality of customization parameters of the SDLC activity is obtained. Moreover, customization effort for customization of the SDLC activity is estimated based on the information associated with the customization parameters.

Abstract: System and method for estimating package implementation effort of software development life cycle (SDLC) activities are disclosed. In an embodiment, information associated with a plurality of configuration parameters of a SDLC activity is obtained. The configuration parameters include an organization, an industry vertical, business criticality of functionalities within the industry vertical, influencing factors and a utilization factor. Further, one or more of configuration factors associated with the SDLC activity are determined based on the information associated with the configuration parameters. Furthermore, functional effort for configuration of the SDLC activity is estimated based on the configuration factors. In addition, information associated with a plurality of customization parameters of the SDLC activity is obtained.

Abstract: Described are methods, systems and computer-readable media storing instructions that when executed on one or more processors execute a process for generating second program code in a statically typed programming language from first program code in a dynamically typed programming language. The first program code contains or, when executed, generates or operates on a dynamically typed array. The second program code may be generated by classifying the dynamically typed array into one of multiple categories, such as homogeneous, heterogeneous, or another, based on the array contents, array usage, and/or user input, and generating the second program code in the statically typed programming language based on the classification(s).

Abstract: Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., at least 10 hours), and more typically greater than 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.

Abstract: Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., at least 10 hours), and more typically greater than 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.

Abstract: Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., at least 10 hours), and more typically greater than 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.

Abstract: Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., at least 10 hours), and more typically greater than 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.

Abstract: Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., at least 10 hours), and more typically greater than 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.